top of page

Media

Press Releases

Intellomx logo.jpg

Intellomx Announces New AI Technology

CAMBRIDGE, UNITED KINGDOM, April 28, 2025 Intellomx (Intelligent OMICS Ltd) today announced the deployment of Intellomx Pilot, delivering rapid identification of novel drugs arising from its existing precision therapeutic
target identification capability, offering pharmaceutical innovators a powerful tool to streamline and de-risk the drug discovery process.

Intellomx logo.jpg

Intellomx Headlines BioTrinity 2025

London, UK – 18 April, 2025- Why has AI not delivered on its ambitious promise in drug discovery? This was the provocative opening posed by Professor Graham Ball during the AI Science Spotlight at BioTrinity in London last week—a question that cut to the heart of today’s drug discovery challenges

Intellomx logo.jpg

Intelligent OMICS Ltd in AI Driven research collaboration with Janssen

London, UK – 1 September, 2023 - Intelligent OMICS Ltd (Intellomx), a leading biotechnology company that applies artificial intelligence (AI) to accelerate drug discovery, today announced a target discovery collaboration with Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to evaluate novel biological targets for the treatment of haematological cancers. The agreement was facilitated by Johnson & Johnson Innovation.

Intellomx logo.jpg

EIN Presswire 10th August 2023

​NOTTINGHAM, UNITED KINGDOM, August 10, 2023 /EINPresswire.com/ --  Intelligent Omics Ltd (Intellomx) is
pleased to announce that it has joined Johnson & Johnson Innovation – JLABS, a premier life science incubator
program.

 

JLABS provides entrepreneurs with the lab space, resources and support needed to bring breakthrough healthcare solutions to patients around the world.

Rob grundy.png

EIN Presswire 1st March 2022

Grundy joins Intellomx

The Senior Management team at Intelligent OMICS is delighted to report the appointment of industry veteran Dr Robert Grundy to the role of VP Business Development.

Contact: rob.grundy@intellomx.com

​

Click photo for details

Cover of OBN CONNECT Autumn 2021.PNG

Front cover and

pages 10 to 13

OBN CONNECT Magazine Autumn 2021

AI: Vive la Revolution

Article from our CEO Dr Simon Haworth with input from Prof Ball plus leaders at Medicines Discovery Catapult and Arctoris regarding our lung cancer assets and the wider implications of AI application for global drug discovery.

Intellomx PR April 2019

images.jpg

Intellomx Press Release about Artificial Intelligence

This Press Release discusses Intellomx and the emerging world of Artificial Intelligence for drug discovery.

Corporate Presentations

Intelligent OMICS + MDC + Arctoris press

Intellomx Update 

Biology 2.0: Combining machine-learning, robotics and biology to deliver drug discovery of tomorrow

This is our latest news on a new collaboration to validate our AI-discovered drug targets

Executive Summary Intellomx BD Q2 2020_0

Intellomx Executive Summary

Intellomx in Short

This is a one page Executive Summary of Intellomx. Please click on the image to the left to download!

Contact Us

Thanks for submitting!

​

Tel. +44 (0)7785 950134

Address: 

Intelligent OMICS Limited
BioCity

1 Pennyfoot Street

Nottingham NG1 1GF

​

© 2025 by Intellomx. Created with Natural Intelligence!!

bottom of page